ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 670

Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA

Biji T. Kurien1, Anil D'souza2, Skyler P. Dillon1, Benjamin F. Bruner3, Timothy Gross4, Judith A. James5, Ira N. Targoff6, Jacen S. Maier-Moore7, Isaac T.W. Harley8, Heng Wang9 and Robert H. Scofield7, 1Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 2Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Harding University, Searcy, AR, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 8Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, 9Das Deutsch Center Clinic for Special Needs Children, Middlefield, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, autoantibodies and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Prolidase is a ubiquitous enzyme found in the cytoplasm.  The enzyme specifically cleaves dipeptides containing C-terminal proline or hydroxyproline, in one of the last steps of collagen metabolism.  Prolidase deficiency is a rare inborn error of metabolism characterized by the secretion of dipeptides in the urine and a variety of clinical manifestations. Only about 50 patients have been reported with the deficiency, of which approximately 10% have systemic lupus erythematosus.  

Methods: A large extended Amish pedigree, having four patients deficient for prolidase, three individuals with heterozygous prolidase activity and eight unaffected individuals, was studied for lupus-associated autoimmunity.  Prolidase genetics and enzyme activity were confirmed.  Antinuclear antibody was measured using indirect immunofluorescence. Antibodies against extractable nuclear antigens were determined by double immunodiffusion, immunoprecipitation, and BioRad 2200 multiplex bead assay.  Serum C1q levels were determined by ELISA.  

Results: Two of the four homozygous prolidase deficient patients had a positive ANA. One had anti-dsDNA antibodies, while another had precipitating anti-Ro60 antibodies.  Three of the four patients had anti-Sm and anti-chromatin by the BioRad 2200 multiplex bead assay. One of the three heterozygous subjects had a positive ANA and immunoprecipitation of a 75,000 MW protein. Serum C1q levels were not changed in the prolidase deficient patients. The unaffected controls had normal prolidase activity and were negative for autoantibodies.

Conclusion: Prolidase deficiency leads to a loss of immune tolerance to lupus-associated autoantigens even without clinical systemic lupus erythematosus.


Disclosure:

B. T. Kurien,
None;

A. D’souza,
None;

S. P. Dillon,
None;

B. F. Bruner,
None;

T. Gross,
None;

J. A. James,
None;

I. N. Targoff,
None;

J. S. Maier-Moore,
None;

I. T. W. Harley,
None;

H. Wang,
None;

R. H. Scofield,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolidase-deficiency-induces-antibodies-to-sm-ro60-and-double-stranded-dna/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology